1. Home
  2. AKBA vs INBK Comparison

AKBA vs INBK Comparison

Compare AKBA & INBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AKBA
  • INBK
  • Stock Information
  • Founded
  • AKBA 2007
  • INBK 1999
  • Country
  • AKBA United States
  • INBK United States
  • Employees
  • AKBA N/A
  • INBK N/A
  • Industry
  • AKBA Biotechnology: Pharmaceutical Preparations
  • INBK Major Banks
  • Sector
  • AKBA Health Care
  • INBK Finance
  • Exchange
  • AKBA Nasdaq
  • INBK Nasdaq
  • Market Cap
  • AKBA 336.2M
  • INBK 289.7M
  • IPO Year
  • AKBA 2014
  • INBK N/A
  • Fundamental
  • Price
  • AKBA $1.80
  • INBK $30.39
  • Analyst Decision
  • AKBA Strong Buy
  • INBK Buy
  • Analyst Count
  • AKBA 1
  • INBK 3
  • Target Price
  • AKBA $7.50
  • INBK $41.00
  • AVG Volume (30 Days)
  • AKBA 1.8M
  • INBK 33.3K
  • Earning Date
  • AKBA 03-13-2025
  • INBK 01-22-2025
  • Dividend Yield
  • AKBA N/A
  • INBK 0.79%
  • EPS Growth
  • AKBA N/A
  • INBK 203.16
  • EPS
  • AKBA N/A
  • INBK 2.88
  • Revenue
  • AKBA $169,879,000.00
  • INBK $117,652,000.00
  • Revenue This Year
  • AKBA N/A
  • INBK N/A
  • Revenue Next Year
  • AKBA $19.31
  • INBK $19.61
  • P/E Ratio
  • AKBA N/A
  • INBK $10.55
  • Revenue Growth
  • AKBA N/A
  • INBK 39.44
  • 52 Week Low
  • AKBA $0.80
  • INBK $24.18
  • 52 Week High
  • AKBA $2.48
  • INBK $43.26
  • Technical
  • Relative Strength Index (RSI)
  • AKBA 28.80
  • INBK 31.34
  • Support Level
  • AKBA $2.07
  • INBK $31.08
  • Resistance Level
  • AKBA $2.17
  • INBK $33.72
  • Average True Range (ATR)
  • AKBA 0.08
  • INBK 1.21
  • MACD
  • AKBA -0.05
  • INBK -0.10
  • Stochastic Oscillator
  • AKBA 4.60
  • INBK 0.00

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

About INBK First Internet Bancorp

First Internet Bancorp is a bank holding company. Through its subsidiaries, it provides commercial real estate (CRE) lending, including nationwide single tenant lease financing and commercial and industrial (C&I) lending, including business banking/treasury management services. The company offers its products and services through the internet and does not have any branches. With operations organized into a single segment called the Commercial Banking segment, it also provides retail banking services.

Share on Social Networks: